181 related articles for article (PubMed ID: 24740199)
21. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
22. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
23. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
[TBL] [Abstract][Full Text] [Related]
24. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
26. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
[TBL] [Abstract][Full Text] [Related]
27. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
Peng DX; Luo M; Qiu LW; He YL; Wang XF
Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.
Yang S; Li H; Liu Y; Ning X; Meng F; Xiao M; Wang D; Lou G; Zhang Y
Med Oncol; 2013 Mar; 30(1):324. PubMed ID: 23254963
[TBL] [Abstract][Full Text] [Related]
30. Roles of functional NFKB1 and β-TrCP insertion/deletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility.
Huo ZH; Zhong HJ; Zhu YS; Xing B; Tang H
Genet Mol Res; 2013 Mar; 12(3):3435-43. PubMed ID: 23546975
[TBL] [Abstract][Full Text] [Related]
31. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
32. Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
Wang C; Winterhoff BJ; Kalli KR; Block MS; Armasu SM; Larson MC; Chen HW; Keeney GL; Hartmann LC; Shridhar V; Konecny GE; Goode EL; Fridley BL
Br J Cancer; 2016 Jun; 114(12):1412-20. PubMed ID: 27253175
[TBL] [Abstract][Full Text] [Related]
33. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
34. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort.
Fortner RT; Ose J; Merritt MA; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopoulou A; Benetou V; Lagiou P; Agnoli C; Mattiello A; Masala G; Tumino R; Sacerdote C; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Weiderpass E; Torhild Gram I; Duell EJ; Larrañaga N; Ardanaz E; Sánchez MJ; Chirlaque MD; Brändstedt J; Idahl A; Lundin E; Khaw KT; Wareham N; Travis RC; Rinaldi S; Romieu I; Gunter MJ; Riboli E; Kaaks R
Int J Cancer; 2015 Sep; 137(5):1196-208. PubMed ID: 25656413
[TBL] [Abstract][Full Text] [Related]
35. Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer.
Zhang L; Wang H; Tian L; Li H
Tohoku J Exp Med; 2016 Jul; 239(3):165-75. PubMed ID: 27302477
[TBL] [Abstract][Full Text] [Related]
36. The Associations of Genetic Variants in E-cadherin Gene With Clinical Outcome of Epithelial Ovarian Cancer.
Juan W; Shan K; Na W; Rong-Miao Z; Yan L
Int J Gynecol Cancer; 2016 Nov; 26(9):1601-1607. PubMed ID: 27779545
[TBL] [Abstract][Full Text] [Related]
37. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
Cao Q; Lu K; Dai S; Hu Y; Fan W
Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
Pylväs-Eerola M; Karihtala P; Puistola U
BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
[TBL] [Abstract][Full Text] [Related]
40. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
